Abstract
AQ4 (1,4-Bis-{[2-(dimethylamino-N-oxide)ethyl]amino}5,8-dihydroxyanthracene-9, 10-dione) is a prodrug designed to be excluded from cell nuclei until bioreduced in hypoxic cells to AQ4, a DNA intercalator and topoisomerase II poison. Thus, AQ4N is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. Five murine tumours (MAC16, MAC26, NT, SCCVII and RIF-1) have been used to investigate the anti-tumour effects of AQ4N. In only one tumour (MAC16) was AQ4N shown to be active as a single agent. However, when combined with methods to increase the hypoxic tumour fraction in RIF-1 (by physical clamping) and MAC26 tumours (using hydralazine) there was a substantial enhancement in anti-tumour effect. Notably, RIF-1 tumours treated with AQ4N (250 mg kg–1) followed 15 min later by physically occluding the blood supply to the tumour for 90 min, resulted in a 13-fold increase in growth delay. When combined with radiation or chemotherapy, AQ4N substantially increased the effectiveness of these modalities in a range of in vivo model systems. AQ4N potentiates the action of radiation in both a drug and radiation dose-dependent manner. Further the enhancement observed is schedule-independent with AQ4N giving similar effects when given at any time within 16 h before or after the radiation treatment. In combination with chemotherapy it is shown that AQ4N potentiates the activity of cyclophosphamide, cisplatin and thiotepa. Both the chemotherapeutic drugs and AQ4N are given at doses which individually are close to their estimated maximum tolerated dose (data not included) which provides indirect evidence that in the combination chemotherapy experiments there is some tumour selectivity in the enhanced action of the drugs.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Acker B and Chaplin D (1987) Potentiation of tumor-cytotoxicity of RSU-1069 by hydralazine: a new approach toward overcoming hypoxic radioresistance. Clin Invest Med 10: B114
Adams GE, Stratford IJ and Nethersell ABW (1989) Manipulation of the oxygenation of tumours: Activation of bioreductive drugs. Br J Radiol BIR Rep 19: 71–75
Bibby MC, Double JA, Ali SA, Fearon KCH, Brennan RA and Tisdale MJ (1987) Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst 78: 539–546
Bibby MC, Double JA and Loadman PM (1988) Unique chemosensitivity of MAC16 tumors to flavone acetic-acid (Lm975, Nsc-347512). Br J Cancer 58: 341–344
Bibby MC, Cronin BP and Phillips RM (1993) Evaluation of the cytotoxicity of the indoloquinone Eo9 in a human colon adenocarcinoma model. Intl J Oncol 3: 661–666
Bremner JCM, Startford IJ, Bowler J and Adams GE (1990) Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer 61: 717–721
Brown JM and Giaccia AJ (1994) Tumor hypoxia – the picture has changed in the 1990s. Int J Radiat Biol 65: 95–102
Brown JM and Wang L-H (1998) Tirapazamine: laboratory data relevant to clinical activity. Anti-Cancer Drug Design 13: 529–539
Brown JM, Zeman EM, Lemmon M and Hirst KV (1987) Selective antitumor therapy with a new class of bioreductive agents. Proc Am Assoc Cancer Res 28: 310
Denekamp J and Harris SR (1975) Tests of two electron affinic sensitizers in vivo using regrowth of an experimental carcinoma. Radiat Res 61: 191–197
Denekemp J, Hill S and Hobson B (1983) Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 19: 271–279
Denny WA, Wilson WR and Hay MP (1996) Recent developments in the design of bioreductive drugs. Br J Cancer 74: S32–S38
Double JA and Ball CR (1975) Chemotherapy of transplantable adenocarcinomas of the colon in mice. Cancer Chemother Rep 59: 1083–1089
Hejmadi MV, McKeown SR, Friery OP, McIntyre IA, Patterson LH and Hirst DG (1996) DNA damage following combination of radiation with the bioreductive drug AQ4N: Possible selective toxicity to oxic and hypoxic tumour cells. Br J Cancer 73: 499–505
Kim IH and Brown JM (1994) Rexoygenation and rehypoxiation in the SCCVII mouse-tumor. Int J Radiat Oncol Biol Physics 29: 493–497
Kivisto KT, Fritz P, Linder A, Friedel G, Beaune P and Kroemer HK (1995) Immunohistochemical localization of cytochrome-P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochem Cell Biol 103: 25–29
McKay JA, Murray GI, Weaver RJ, Ewen SWB, Melvin WT and Burke MD (1993) Xenobiotic-metabolizing enzyme expression in colonic neoplasia. Gut 34: 1234–1239
McKeown SR, Hejmadi MV, McIntyre IA, McAleer JJA and Patterson LH (1995) AQ4N – an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 72: 76–81
McKeown SR, Friery OP, McIntyre IA, Hejmadi MV, Patterson LH and Hirst DG (1996) Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer 74: S39–S42
McKeown SR, Friery O, Gallagher R, Murray M, Clarke C, Patterson LH and Hirst DG (1998) Enhancement of cyclophosphamide anti-tumour activity with bioreductive drugs AQ4N and tirapazamine. Br J Cancer 78: 45
Massaad L, Dewaziers I, Ribrag V, Janot F, Morizet J, Beaune PH, Gouyette A and Chabot GG (1993) Screening of main drug-metabolizing-enzymes in mouse and human colon tumours. Bull Cancer 80: 397–407
Moore JV (1988) The dynamics of tumour cords in an irradiated mouse mammary carcinoma with a large hypoxic cell component. Jpn J Cancer Res (Gann) 79: 236–243
Murray GI, Weaver RJ, Paterson PJ, Ewen SWB, Melvin WT and Burke MD (1993) Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathology 169: 347–353
Murray MM, Robson T, Gallagher R, Patterson LH, Hirst DG and McKeown SR (1998) Increased expression of cytochrome P450 isoforms in mouse tumours and their role in the enhanced activation of the bioreductive drug, AQ4N. Br J Cancer 78: 710
Patterson LH (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA-binding agents – a new class of bioredutive agent. Cancer Metastas Rev 12: 119–134
Patterson LH and Raleigh SM (1998) Reductive metabolism: its application to prodrug activation. In: Drug Metabolism Towards the Next Millennium, Gooderham N J (eds), pp, 72–79, IOS Press: Amsterdam
Patterson LH, Craven MR, Fisher GR and Teesdalespittle P (1994) Aliphatic amine N-oxides of DNA-binding agents as bioreductive drugs. Oncol Res 6: 533–538
Patterson AV, Saunders MP, Chinje EC, Patterson LH and Stratford IJ (1998) Enzymology of tirapazamine metabolism: a review. Anti-Cancer Drug Design 13: 541–573
Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM and Orr S (2000) Antiumour prodrug development using cytochrome P450 (CYP) mediated activation. Anti-Cancer Drug Design, (in press)
Quinn PKM, Bibby MC, Cox JA and Crawford SM (1992) The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumors. Br J Cancer 66: 323–330
Raleigh SM, Wanogho E, McKeown SR, Burke MD and Patterson LH (1998) Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-Oxide prodrug. Int J Radiat Biol Chem Physics 42: 763–767
Siim BG, Menke DR, Dorie MJ and Brown JM (1997) Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 57: 2922–2928
Smith PJ, Blunt NJ, Desnoyers R, Giles Y and Patterson LH 1997 a) DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother Pharmacol 39: 455–461
Smith PJ, Desnoyers R, Blunt N, Giles Y, Patterson LH and Watson JV 1997 b) Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Cytometry 27: 43–53
Stratford IJ and Workman P (1998) Bioreductive drugs into the next millenium. Anti-Cancer Drug Design 13: 519–528
Stratford IJ, Adams GE, Godden J, Howells N and Timpson N (1989) Induction of tumour hypoxia post-irradiation: A method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol 55: 411–422
Stratford IJ, Godden J, Howells N, Embling P and Adams GE (1987) Manipulation of tumour oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumours. Radiat Res 2: 737–742
Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA and Kallman RF (1980) A new mouse Tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 64: 595–604
Wilson WR, Denny WA, Pullen SM, Thompson KM, Li AE, Patterson LH and Lee HH (1996) Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br J Cancer 74: S43–S47
Workman P and Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastas Rev 12: 73–82
Workman P, Balmain A, Hickman JA, McNally NJ, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC and Wallace J (1988) UKCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58: 109
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Patterson, L., McKeown, S., Ruparelia, K. et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 82, 1984–1990 (2000). https://doi.org/10.1054/bjoc.2000.1163
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1163
Keywords
This article is cited by
-
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Cancer Chemotherapy and Pharmacology (2016)
-
Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases
Clinical & Experimental Metastasis (2015)
-
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
Cancer Chemotherapy and Pharmacology (2012)
-
Exploiting tumour hypoxia in cancer treatment
Nature Reviews Cancer (2004)
-
Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N
Cancer Gene Therapy (2003)